• An alternative approach to the administration

  2024-02-19

  

  An alternative approach to the administration of ADO agonists is to amplify the actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK). Inhibition of AK has the net effect of potentiating the local concentration and the effects of ADO in the extracellular compartment. T

• We have previously reported that interfering with actin asse

  2024-02-19

  

  We have previously reported that interfering with VPS34-IN1 assembly dynamics by knocking down cofilin-1 in hMSCs increased polymerized actin that promoted osteoblast cell differentiation through a mechanism of enhancing focal adhesion kinase (FAK), p38 and c-Jun N-terminal kinase (JNK) signaling (

• Another open question is whether GABA and ACh are

  2024-02-19

  

  Another open question is whether GABA and ACh are released from the same synaptic vesicles, or even the same presynaptic terminals. Multi-transmitter neurons may either function through co-release, in which multiple neurotransmitters are packaged into the same presynaptic terminal and are therefore

• Our sample is representative of mRCC treated with

  2024-02-19

  

  Our sample is representative of mRCC treated with sunitinib. However, the results from CCC setting have limited inference due to small exploratory sample (n = 51). Additionally, the significance of survival differences in CCC according to AXL staining is tangential. Unfortunately, we were unable to

• In our studies of leucine and BCH in

  2024-02-19

  

  In our studies of leucine and BCH in pancreatic islets and clonal insulin cell lines, we noticed that leucine was a slightly stronger stimulant of insulin release. Previous studies showed that leucine can be metabolized to CO2[11], [12], [13], [14] and can increase acetoacetate in pancreatic islets

• br Material and methods br Results br Discussion This

  2024-02-19

  

  Material and methods Results Discussion This study explores the hypothesis that ASK1, via transcriptional upregulation by E2F1, molecularly defines AT that supports a dys-metabolic obese phenotype in humans. We demonstrate associations between increased visceral-AT ASK1 expression and multi

• Given that the FST protocol

  2024-02-18

  

  Given that the FST protocol for mice does not engage the exposure to a previous stressful session, posits that Agtr1a levels could be kept higher by basal glutamatergic transmission rather than by stressful stimuli as postulated before. To address this possibility, we used the EMBL-EBI Expression At

• br Introduction Nonalcoholic fatty liver disease

  2024-02-18

  

  Introduction Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic spectrum of liver pathologies associated with excessive accumulation of fat in the liver. This spectrum is continuous but can be graded based on pathological features; in increasing severity, these are: bland steatosis,

• DRiPs also contribute to formation

  2024-02-10

  

  DRiPs also contribute to formation of protein EIPA that result from dysregulation of proteostasis, during which the proteolytic machinery is unable to process and degrade defective proteins (Tyedmers et al., 2010). Aggregation of poly-ubiquitinated proteins has been observed in different cell types

• Preliminary results of studies sponsored by the

  2024-02-10

  

  Preliminary results of studies sponsored by the manufacturer of ETC-1002 have also shown positive results for monotherapy in statin-intolerant patients and for the combined use of the ACL inhibitor plus other cholesterol-reducing agents. In patients with a documented history of intolerance to statin

• br Disclaimer Statement br Acknowledgments br Introduction M

  2024-02-10

  

  Disclaimer Statement Acknowledgments Introduction Metabolic changes are a common feature of cancerous tissues. Mutations in oncogenes and tumor suppressor genes cause alterations to multiple intracellular signaling pathways that rewire tumor cell metabolism and re-engineer it to allow enhan

• br Declaration of interest br Funding br

  2024-02-10

  

  Declaration of interest Funding Introduction The endocrine disruptor bisphenol A (BPA) is a high-production chemical used in several consumer products, including polycarbonate bottles, epoxy resins, dental sealants, and thermal paper receipts (Geens et al., 2012). Importantly, BPA monomers

• The reduction of heterodimerization of

  2024-02-10

  

  The reduction of heterodimerization of KOR and APJ by both doses of apelin found in the present study may result in inducing protective effects of apelin on the myocardium imposed to high pressure in renovascular hypertension conditions. The finding that apelin in both doses reduced heterodimerizati

• In light of several reports

  2024-02-09

  

  In light of several reports of defects in memory-related tasks for the dysbindin-deficient mice (Cox et al., 2009, Takao et al., 2008), it was rather unexpected that an enhancement of CA3–CA1 LTP was observed in our investigation as well as in another independent study (T.T. Tang et al., 2009). The

• fda approved Gratifyingly compound also demonstrated improve

  2024-02-09

  

  Gratifyingly, compound also demonstrated improved physicochemical properties with significant improvement in aqueous solubility. Compound was sufficiently potent to determine its pharmacokinetic (PK) and pharmacodynamics (PD); data is summarized in . shows ADME characteristics for compound and

15399 records 192/1027 page Previous Next First page 上5页 191192193194195 下5页 Last page